ArticleHemaSphere2021

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.

Ruben A Mesa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.